LAMPERT MARK N 4
4 · ARENA PHARMACEUTICALS INC · Filed Oct 21, 2003
Insider Transaction Report
Form 4
LAMPERT MARK N
Director10% Owner
Transactions
- Sale
Common Stock
2003-10-17$7.69/sh−2,911,000$22,385,590→ 4,520,212 total(indirect: See Footnotes)
Footnotes (2)
- [F1]The shares reported in this response are beneficially owned by Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") (1,376,977 shares); Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P.") (883,884 shares); BVF Investments, L.L.C., a Delaware limited liability company ("Investments") (2,259,351 shares); and by BVF Partners L.P., a Delaware limited partnership ("Partners"), and by its general partner BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of BVF, L.P. and BVF2, L.P. and is the manager of Investments. Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of common stock described herein as being beneficially owned by Investments.
- [F2]Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. Mr. Lampert disclaims beneficial ownership of shares reported in this response, except to the extent that he has a pecuniary interest therein. Mr. Lampert is currently a director of Arena Pharmaceuticals, Inc.